Replies to post #4361 on Antares Pharma, Inc. (ATRS)

[H2R]

Xyosted Sept. 29 PDUFA Goal Date
Launch planning resumed (contingent on approval), offers to sales reps on-going.

Not quite 2 months :)

I hope that does move the needle (choose which one, they have a few :)

By the way, that was SmithOnStocks' contention with this article: https://smithonstocks.com/antares-pharma-approval-of-xyosted-on-or-before-september-29-2018-is-highly-probable-atrs-buy-2-12/

[H2R]

On the EpiPen, nothing firm, but the Company's line for a while now:

Moving on to our Teva development products. The first product is a generic equivalent to Mylan’s EpiPen, the epinephrine auto injector. Teva is still anticipating a 2018 launch of a generic EpiPen, and we receive additional POs to supply auto injectors in 2018, beyond the initial launch quantities already shipped. This product is on an active review by the FDA following the ANDA pathway. And we continue to believe, it could be a significant contributor to the future growth of Antares. To-date, we have shipped Teva $22 million worth of devices at cost plus margin. And once the product is potentially approved and launched, we will also receive mid to high single digit royalties on in-market sales of the product. We will also receive a onetime milestone payment upon approval.

https://seekingalpha.com/article/4195823-antares-pharma-inc-atrs-ceo-bob-apple-q2-2018-results-earnings-call-transcript?part=single

I still have not seen much movement on this one. If some progress were to be PR'ed, we would see some PPS action I believe. That's another big deal.